Brain Power Infusion (Citicoline + Cerebrolysin)

The Brain Power Infusion at ARCADA Medicentrum delivers two of the most clinically researched neuroprotective compounds — Citicoline and Cerebrolysin — directly into the bloodstream. Citicoline (CDP-choline) is a naturally occurring compound that supports phosphatidylcholine synthesis in neuronal membranes, enhancing acetylcholine neurotransmission and protecting neurons from ischaemic damage. Cerebrolysin is a neuropeptide mixture derived from porcine brain protein concentrate, used in neurological medicine for acute ischaemic stroke, traumatic brain injury, and cognitive decline — with a multi-decade European clinical evidence base. Together, they form a powerful synergistic protocol for individuals managing brain injury recovery, cognitive deterioration, or post-stroke neurological deficits. At ARCADA, this infusion is offered in the context of a clinic deeply experienced in neurological rehabilitation.

The Brain Power Infusion at ARCADA Medicentrum combines two pharmaceutically distinct neuroprotective agents that have complementary mechanisms of action: **Citicoline (CDP-choline):** A naturally occurring intermediate in the biosynthesis of phosphatidylcholine, the dominant phospholipid in neuronal membranes. IV Citicoline has demonstrated in clinical trials to: stabilise neuronal membrane integrity after ischaemic injury, enhance cerebral blood flow, increase dopamine and norepinephrine levels (supporting alertness, motivation, and mood), and accelerate neural recovery after stroke. It has a well-established European safety profile and is used in neurological practice across multiple countries. **Cerebrolysin:** A standardised mixture of neuropeptides and amino acids obtained from porcine brain protein, acting as a neurotrophic-like agent. Its documented mechanisms include: inhibition of apoptosis (programmed neuronal cell death) in ischaemic and hypoxic tissue, stimulation of neuroplasticity via BDNF and NGF mimicry, protection of neuronal mitochondria, and reduction of excitotoxic glutamate effects. Cerebrolysin has been studied in randomised controlled trials for acute ischaemic stroke (20–30 mL/day × 10–21 days), Alzheimer's disease, and vascular dementia, and is registered as a prescription-grade treatment in multiple European countries. At ARCADA, the Brain Power Infusion is particularly relevant for: patients in post-stroke or post-TBI recovery who want to complement their physiotherapy/neurorehabilitation with pharmacological neuroprotection, individuals experiencing age-related cognitive decline or vascular dementia onset, those recovering from carbon monoxide poisoning or hypoxic brain injury, and clients seeking cognitive performance optimisation under medical supervision. Each session is administered by nursing staff under medical oversight in the Medicentrum infusion suite, running approximately 60 minutes. A full course of 10–20 sessions (equivalent to the clinically validated protocol from stroke RCTs) is recommended for therapeutic effect on neurological indications; shorter 5-session courses are used for cognitive enhancement goals. Pre-course assessment includes neurological history review and contraindication screening. Book via +420 604 772 988.